Patents by Inventor Timothy T. Hla

Timothy T. Hla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APOM-FC FUSION PROTEINS FOR TREATING LUNG DISEASES
    Publication number: 20210380665
    Abstract: Provided herein are methods of treating lung disease using fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG).
    Type: Application
    Filed: October 11, 2019
    Publication date: December 9, 2021
    Applicant: Children's Medical Center Corporation
    Inventors: Timothy T. Hla, Steven L. Swendeman, Mark Puder, Lois Smith
  • APOM-FC FUSION PROTEINS AND USES THEREOF
    Publication number: 20210032310
    Abstract: Provided herein are engineered fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG). In some embodiments, the ApoM-Fc fusion protein further comprises a signal peptide (e.g., IL-2 signal peptide) fused to the ApoM, allowing the fusion protein to be secreted once expressed recombinantly. Methods of using the ApoM-Fc fusion protein or the sponge variants in the treatment of various diseases or disorders are provided.
    Type: Application
    Filed: August 15, 2018
    Publication date: February 4, 2021
    Applicant: Children's Medical Center Corporation
    Inventors: Timothy T. Hla, Steven L. Swendeman, Lois Smith
  • ApoM-Fc fusion proteins, complexes thereof with sphingosine 1-phosphate (S1P), and methods for treating vascular and non-vascular diseases
    Patent number: 10870689
    Abstract: The present disclosure is directed to an engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperone derived from an Apolipoprotein M (ApoM)-Fc fusion protein having an extended half life in vivo. The disclosed ApoM-Fc fusion protein provides a safe, efficient and effective means of delivering S1P to endothelial cells and to all tissues of the body.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: December 22, 2020
    Assignee: The Children's Medical Center Corporation
    Inventors: Timothy T. Hla, Steven L. Swendeman, Annarita DiLorenzo, Teresa Sanchez
  • APOM-FC FUSION PROTEINS, COMPLEXES THEREOF WITH SPHINGOSINE 1-PHOSPHATE (S1P), AND METHODS FOR TREATING VASCULAR AND NON-VASCULAR DISEASES
    Publication number: 20190185545
    Abstract: The present disclosure is directed to an engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperone derived from an Apolipoprotein M (ApoM)-Fc fusion protein having an extended half life in vivo. The disclosed ApoM-Fc fusion protein provides a safe, efficient and effective means of delivering S1P to endothelial cells and to all tissues of the body.
    Type: Application
    Filed: August 15, 2017
    Publication date: June 20, 2019
    Applicant: Children's Medical Center Corporation
    Inventors: Timothy T. Hla, Steven L. Swendeman, Annarita DiLorenzo, Theresa Sanchez